2023-04-06 06:28:02 ET
Summary
- Biogen and Eisa compared the effects of their drug Leqembi against the combined placebo decline rather than against the different rates of decline for APOE4 carriers and non-carriers.
- This made Leqembi look more effective for non-carriers than it actually was while making APOE4 homozygotes look like they were actually getting worse on the drug compared to the placebo.
- Cassava Sciences made simufilam look more effective than it actually was by processing those with the least cognitive impairment first and those with the most cognitive impairment last.
- Anavex said that blarcamesine produced a 2-point improvement in MMSE scores at 57 weeks in its phase 2a trial, but this was in a subgroup of patients.
- In its phase 2b/3 clinical trial, Anavex combined the 30mg and 50mg groups perhaps in order to boost the total number of participants, but the 50mg group was the one who likely benefitted from the drug.
For further details see:
Biogen And Eisai, Cassava Sciences, And Anavex: Clinical Trial Results In Need Of Revisions